Send us a text

A slow-burning disease like Charcot Marie Tooth can fool even the best trials. Scores swing with sleep and stress, not biology, while tiny changes accumulate out of sight. We set out to replace guesswork with measurement and show how the right biomarkers can compress timelines, cut costs, and turn promising science into treatments that matter.

First, we unpack the measurement problem and why functional scales are too noisy for a disease that changes over years. Then we get concrete. MRI fat fraction reveals muscle-to-fat replacement in just 43 days, letting us see whether a therapy slows degeneration without waiting 18 months for a clinic score to budge. From there we move molecular: proteomics shows drops in extracellular matrix and neuronal development proteins alongside rising metabolic stress signals, reframing CMT as both a structural and metabolic disorder. That shift sets up a powerful case study—sorbitol accumulation traced to an enzyme defect—where a biomarker connected patients to a drug already in development for another condition.

We also highlight the rise of digital biomarkers that live where patients do. Wearables capture fatigue, drop foot, and real stair performance over weeks, producing real-world evidence that complements imaging and blood markers. None of this works without patient partnership, so we talk candidly about biobanks, why longitudinal samples are non-negotiable, and how skin cells reprogrammed into neurons enable personalized drug screens without invasive nerve biopsies. Finally, we tackle the big strategic question: will a universal marker like neurofilament light unlock progress across 100-plus genetic subtypes, or do we need a unique fingerprint for each?

If you care about faster trials, smarter endpoints, and bringing CMT treatments to the pharmacy shelf sooner, this deep dive is for you. Subscribe, share with someone in the CMT community, and leave a review with your take: master biomarker or many subtype markers?

Ways to take action now

1) Donate blood at an HNF Roadshow:
You can donate blood for biomarker research at an HNF Roadshow near you. Click on the “Location” tab to view 2026 dates and sites:

2) Join Studies & Donate blood at the CMT Summit + Retreat:
Attending the Summit? You can also donate blood on-site to support HNF’s biobank and biomarker discovery efforts—helping accelerate progress toward FDA-qualified measures and future treatments.

3) Join or update GRIN:
If you’re already in the GRIN Registry, please log in and complete any annual updates—every data point strengthens the research.

Watch webinar

Thanks for listening! Learn more at hnf-cure.org and subscribe for more updates on CMT research and advancements.

Send us a text

If resilience feels like a buzzword, consider this a reset. We explore a lived-in roadmap shaped by the Charcot-Marie-Tooth community, where change is constant and the goal isn’t to bounce back—it’s to move forward with smarter tools, stronger ties, and a lighter emotional weight. With Lily Sander, the 2025 MDA National Ambassador, and Estela Lugo from the Hereditary Neuropathy Foundation, we trace how connection creates “disabled joy,” a kind of relief that comes from being understood without translation. That recognition becomes fuel for action, whether it’s showing up at advocacy days, finding candid advice in digital groups, or letting positive representation shift your inner narrative.

Estela reframes resilience as the overlap of physical and emotional capacity. She names the hidden fall risks—blurred boundaries, comparison traps, people-pleasing—and offers a practical check-in using the Hawkins Scale of Emotions to move from heavy states like shame and fear toward courage, pride, and desire. We dig into fear management that’s actually usable: scout accessibility, use assistive tools without apology, and remember past wins as evidence. The message isn’t perfection; it’s honest capacity and self-grace, especially after stumbles. Purpose does the rest, turning the act of getting back up into a habit you can rely on.

We also get tactical with planning. Keep the vision, flex the route. If the dream is travel, adapt the method—cruises, companions, accessible gear, or remote work that funds the path. Service ties it all together: when you give back, fear shrinks, and pride grows, and your story helps someone else stand taller. We end with a memorable metaphor: the Alter-G treadmill that lifts body weight is also a lens for life. Community, flexible goals, and self-compassion are your emotional Ultra Gs—tools that reduce drag so you can keep moving. Subscribe, share this with a friend who needs a lift today, and tell us: what’s your Alter-G?

Watch this HNF + MDA webinar series on CMT and more here!

Connect with CMT Community at the 2026 CMT Summit & Retreat on 4/16-18 in Ellicott City, MD. Register here!

Thanks for listening! Learn more at hnf-cure.org and subscribe for more updates on CMT research and advancements.

Send us a text

Wading through the Social Security Disability Benefits process feels like navigating a bureaucratic labyrinth—one that becomes even more daunting when you're dealing with Charcot-Marie-Tooth disease. From chronic muscle weakness to mobility challenges, CMT sufferers face enough hurdles without fighting government red tape.

This episode cuts through the confusion, offering a specialized roadmap for CMT patients seeking disability benefits. We break down the two distinct pathways—SSDI (tied to your work history and FICA contributions) and SSI (needs-based with strict financial requirements)—and explain critical differences in waiting periods, payment amounts, and healthcare access. While SSDI requires five months before your first payment and a staggering two-year wait for Medicare, SSI offers immediate Medicaid eligibility despite its lower monthly payments and tight asset restrictions.

The heart of our discussion examines the five-step evaluation process used by Social Security, revealing why initial denial rates approach a shocking 90%. We walk through each step: the earnings threshold, severity requirements, medical listings, past work assessment, and the "mythical, hypothetical" test of whether any job exists nationwide that you could theoretically perform. For CMT specifically, we examine how the condition gets evaluated under peripheral neuropathy listings and why most cases win or lose at steps four and five.

Most crucially, we share the documentation strategies that transform denial into approval. Beyond diagnosis, you need objective medical evidence translating symptoms into functional limitations—EMG studies, gait analysis, and the all-important Residual Functional Capacity form that connects your medical reality to work capabilities. We explore how age transforms approval chances through the "grid rules," why consistent medical records matter, and how attorneys working on contingency can dramatically improve your odds at the critical hearing stage.

Ready to tackle the system? Listen now, take notes, and prepare to advocate effectively for the benefits you deserve.

Learn more at: https://www.hnf-cure.org/cmt/patient-resources/legal-rights-and-benefits/

Thanks for listening! Learn more at hnf-cure.org and subscribe for more updates on CMT research and advancements.